CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan contact

- Last updated on GMT

CFDA accepts WuXi-MedImmune’s IND for new mAb

Related tags: Investigational new drug, Wuxi

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis. 

In September 2012, MedImmune, the biologics R&D arm of AstraZeneca, and WuXi formed the joint venture to develop and commercialize MEDI5117, a novel, investigational, long-acting mAb for autoimmune and inflammatory diseases. 

WuXi completed all CMC (chemistry, manufacturing and control), nonclinical, and clinical sections of the dossier, and the wholly owned subsidiary of the joint venture filed an IND for it with the Jiangsu provincial FDA as a Class 1 therapeutic biologic in December 2014.  WuXi's biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi, China, passed the Jiangsu FDA's onsite inspections in January. 

The IND application has now been entered into the system of the CFDA for technical review. WuXi will continue to provide manufacturing for the program at its biologics facilities, as well as provide local regulatory, pre-clinical, and clinical trial support. 

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars